Walleye Capital LLC Trims Stock Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Walleye Capital LLC trimmed its position in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 25.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,329 shares of the biopharmaceutical company’s stock after selling 2,481 shares during the period. Walleye Capital LLC’s holdings in Horizon Therapeutics Public were worth $771,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of Horizon Therapeutics Public by 45.3% in the first quarter. EverSource Wealth Advisors LLC now owns 879 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 274 shares during the last quarter. First National Bank of Omaha grew its stake in shares of Horizon Therapeutics Public by 18.6% in the first quarter. First National Bank of Omaha now owns 81,316 shares of the biopharmaceutical company’s stock worth $8,556,000 after acquiring an additional 12,761 shares during the last quarter. L.M. Kohn & Company purchased a new stake in shares of Horizon Therapeutics Public in the first quarter worth $395,000. Neuberger Berman Group LLC grew its stake in shares of Horizon Therapeutics Public by 8.5% in the first quarter. Neuberger Berman Group LLC now owns 374,307 shares of the biopharmaceutical company’s stock worth $39,381,000 after acquiring an additional 29,377 shares during the last quarter. Finally, Toroso Investments LLC grew its stake in shares of Horizon Therapeutics Public by 206.4% in the first quarter. Toroso Investments LLC now owns 15,508 shares of the biopharmaceutical company’s stock worth $1,632,000 after acquiring an additional 10,447 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Horizon Therapeutics Public Stock Up 0.8 %

HZNP stock opened at $63.48 on Wednesday. Horizon Therapeutics Public Limited has a fifty-two week low of $57.84 and a fifty-two week high of $120.54. The business’s 50-day moving average is $69.08 and its two-hundred day moving average is $86.58. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.79 and a current ratio of 4.05. The company has a market cap of $14.62 billion, a price-to-earnings ratio of 19.59, a P/E/G ratio of 1.58 and a beta of 1.21.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.29). Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The firm had revenue of $876.40 million during the quarter, compared to the consensus estimate of $938.82 million. During the same period in the prior year, the company posted $1.62 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts forecast that Horizon Therapeutics Public Limited will post 4.23 earnings per share for the current year.

Insiders Place Their Bets

In other Horizon Therapeutics Public news, EVP Andy Pasternak sold 4,850 shares of the company’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $82.57, for a total value of $400,464.50. Following the completion of the sale, the executive vice president now owns 34,047 shares in the company, valued at $2,811,260.79. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Sean M. Clayton purchased 745 shares of Horizon Therapeutics Public stock in a transaction on Thursday, August 4th. The stock was acquired at an average price of $66.67 per share, for a total transaction of $49,669.15. Following the completion of the transaction, the executive vice president now directly owns 745 shares in the company, valued at approximately $49,669.15. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Andy Pasternak sold 4,850 shares of the company’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $82.57, for a total value of $400,464.50. Following the completion of the sale, the executive vice president now owns 34,047 shares of the company’s stock, valued at approximately $2,811,260.79. The disclosure for this sale can be found here. Insiders sold a total of 5,022 shares of company stock worth $415,089 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on HZNP shares. StockNews.com cut Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. SVB Leerink downgraded Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. TheStreet downgraded Horizon Therapeutics Public from a “b” rating to a “c+” rating in a report on Tuesday, August 16th. UBS Group downgraded Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and lowered their price target for the company from $137.00 to $71.00 in a report on Thursday, August 4th. Finally, BMO Capital Markets lowered their price target on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating on the stock in a report on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.22.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Featured Stories

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.